Form 8-K - Current report:
SEC Accession No. 0001193125-23-219539
Filing Date
2023-08-24
Accepted
2023-08-24 07:30:31
Documents
16
Period of Report
2023-08-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d479429d8k.htm   iXBRL 8-K 31686
2 EX-10.1 d479429dex101.htm EX-10.1 61547
3 EX-99.1 d479429dex991.htm EX-99.1 12191
7 GRAPHIC g479429dsp5.jpg GRAPHIC 2446
8 GRAPHIC g479429dsp5a.jpg GRAPHIC 4597
  Complete submission text file 0001193125-23-219539.txt   256608

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA teva-20230821.xsd EX-101.SCH 2844
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE teva-20230821_lab.xml EX-101.LAB 17167
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE teva-20230821_pre.xml EX-101.PRE 10784
10 EXTRACTED XBRL INSTANCE DOCUMENT d479429d8k_htm.xml XML 3367
Mailing Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 5 BAZEL ST PO B 3190 PETACH TIKVA L3 49131
Business Address 5 BAZEL ST P O B 3190 PETACH TIKVA L3 49131 9729267267
TEVA PHARMACEUTICAL INDUSTRIES LTD (Filer) CIK: 0000818686 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-16174 | Film No.: 231198917
SIC: 2834 Pharmaceutical Preparations